Testicular Cancer: Symptoms, Diagnosis, Treatment & Red Flags

Testicular cancer refers primarily to malignant germ cell tumours arising from the testicular parenchyma after puberty, with seminomatous and non-seminomatous lineages dominating treatment algorithms. Stromal tumours, lymphoid infiltrates and paratesticular processes exist, yet when nurses hear “testicular cancer” on a board-round it usually means a germ cell diagnosis that will lean on histology plus the serum tumour-marker triad. Seminomas display sheets of uniform cells with lymphocytic stroma, while NSGCT encompasses embryonal, yolk sac, choriocarcinoma and teratomatous elements—often admixed—so mixed pathology is common rather than exceptional.

Biologically, GCTs retain developmental plasticity; this explains brisk beta-hCG secretion from trophoblastic components, AFP from yolk-sac differentiation, and why marker kinetics after orchidectomy matter as much as static imaging when clinicians judge chemotherapy depth or surveillance intensity. Nursing relevance starts with recognising that “CT-negative, marker-positive” relapse is a treated entity in many protocols, not a reassurance finding.

Care is multidisciplinary—urology, medical oncology, radiation oncology, pathology, fertility services, clinical genetics when familial clustering or differences of sex development coexist—and benefits from youth-friendly psycho-oncology because median age at diagnosis sits in early adulthood with decades of survivorship ahead.

AJCC TNM staging combines primary tumour extent (pT), nodal volume (N—retroperitoneum is the classic landing zone), distant metastasis (M) and—for GCTs—S serum marker strata (Sx–S3) where LDH, AFP and beta-hCG each contribute points in the 8th-edition schema. For advanced NSGCT, the International Germ Cell Consensus Classification (IGCCCG) layers on non-pulmonary visceral metastases and extreme marker thresholds to label good, intermediate or poor prognosis—this drives chemotherapy cycle number and intensity more than any single CT slice.

↔On a small screen, swipe or scroll sideways to see the full table.

Numbers in your hospital’s synoptic report and MDT letter override ward mnemonics; always copy the official pT/NM/S wording into handover.

Most patients notice a painless, firm testicular lump or diffuse testicular enlargement that does not resolve after antibiotics. Heaviness or dull ache can accompany—not contradict—malignancy and should not be dismissed as epididymitis without imaging. Central nervous system symptoms (headache, seizures, cranial neuropathy) can herald choriocarcinomatous spread despite an otherwise “quiet” primary.

Advanced or bulky presentations

• Supraclavicular nodes, palpable abdominal mass, or obstructive nephropathy from retroperitoneal encasement.
• Hyperthyroidism mimic or gynaecomastia when hCG is astronomically high.
• Heavy fatigue, anorexia, or night sweats overlapping—but not equal to—features seen in lymphoma when nodes are massive.

Cryptorchidism (even corrected), prior contralateral GCT, family history in first-degree relatives, germ cell neoplasia in situ risk states, and certain intersex chromosomal patterns elevate incidence. Population incidence has risen in industrialised cohorts for incompletely understood environmental/genetic reasons; nursing history should capture infertility work-ups, earlier scrotal surgery, and HIV—HIV-positive men experience higher seminoma rates per surveillance summaries, yet curative pathways mirror the general model when performance status allows.

Examination & imaging

Firm, irregular, non-transilluminating intra-testicular masses prompt urgent ultrasound. Extra-testicular lesions more often prove benign, whereas intra-testicular hypoechoic vascularised solid tissue tilts toward malignancy—still, the definitive step is surgical pathology after inguinal orchidectomy.

Laboratory investigations

Draw AFP, beta-hCG (include hook-effect awareness for massive titre labs) and LDH alongside renal panel and LFTs; repeat markers serially after orchidectomy when staging decisions hinge on half-lives. LDH is nonspecific but contributes to formal staging and prognosis.

Staging imaging

Contrast CT chest/abdomen/pelvis is standard for nodal and visceral metastases; MRI brain enters when neurology or extreme choriocarcinoma risk features appear. PET-CT is not a routine first-line stager for GCT in most guidelines—use only when MDT assigns it.

1. Suspected mass → same-week ultrasound + tumour markers + refer urology/oncology.
2. Highly suspicious intra-testicular mass → schedule radical inguinal orchidectomy; avoid trans-scrotal violation.
3. Post-op stage I pure seminoma → risk-adapted surveillance vs low-dose adjuvant radiation vs single-agent carboplatin—choice is MDT + patient preference.
4. Post-op NSGCT stage I → surveillance vs BEP ×1 adjuvant vs primary RPLND—dependent on vascular invasion and local trial conventions.
5. Metastatic NSGCT good risk → BEP ×3 typical; intermediate/poor BEP ×4 ± dose-dense strategies per trial context.
6. Residual masses post-chemo → PET-negative teratomatous logic may still need resection—coordinate theatre literacy and pain assessment.

Epididymo-orchitis (fever, urinary symptoms, hyperaemic Doppler), traumatic haematocele, adenomatoid tumour, Leydig-cell adenoma, sarcoid or infarction can mimic malignancy. Metastases to the testis from prostate carcinoma, lung primaries or lymphoma exist but are rarer; persistent solid intra-testicular architecture should bias toward orchidectomy rather than endless antibiotic trials.

Surgery

Radical inguinal orchidectomy remains diagnostic and therapeutic. Partial orchidectomy is exceptional and MDT-governed. Retroperitoneal lymph-node dissection is staging or therapeutic in selected NSGCT pathways and carries ejaculatory/autonomic morbidity—pre-op fertility discussion is mandatory when nerve-sparing intent exists.

Medical oncology

Cisplatin-based regimens anchor metastatic curative intent; etoposide replaces older vinblastine in BEP. High bleomycin cumulative exposure amplifies lung fibrosis risk—nurses should daily query cough, dyspnoea, and incentive spirometry adherence when used. Antiemetics align with local emetogenicity policy—commonly combining 5-HT₃ antagonists such as ondansetron with NK1 pathways; add metoclopramide or others only per charted prescription.

Radiotherapy

Adjuvant para-aortic radiation is an option for some stage I seminomas; teach gastrointestinal and fatigue expectations and emphasise protection/shielding conversation for the contralateral testis when relevant.

Surveillance

Stage I pathways lean on schedules combining physical exam, markers and interval imaging—non-adherence drives relapse detection delay; give patients written timelines and psychology referrals when scan anxiety paralyses attendance.

• Pre-cisplatin: optimise hydration, review nephrotoxins, trend creatinine and magnesium; link with CKD nursing bundles when eGFR is borderline.
• Bleomycin cycles: monitor SpO₂, auscultate lungs, teach “report cough early”; some centres perform spirometry/PFT surveillance—know your unit’s trigger.
• Neutropenia: educate Febrile Neutropenia hotline use; align filgrastim administration with pharmacy cold-chain rules.
• Vascular access hygiene and extravasation drills matter with vesicant platinum salts—verify patency before each cisplatin push or infusion.
• Survivorship MDT: transition primary care with cardiovascular risk screening, hypogonadism evaluation, and counselling about second solid tumours—especially after radiotherapy fields involving abdomen where kidney or bladder cancers feature in late surveillance literature.

Treatment-related neuropathy, ototoxicity, pulmonary fibrosis, cardiovascular disease, metabolic syndrome, anxiety/depression, infertility, and therapy-related acute leukaemia (especially with high cumulative etoposide) are all recognised—documentation should reflect structured toxicity grading so adjustments happen before irreversible organ injury.

There is no population screening programme akin to mammography; clinician-facing prevention is early referral of persistent testicular abnormalities, correction of undescended testes in childhood where appropriate, and genetic counselling when syndromic cues appear. Teach motivated high-risk survivors monthly self-examination of the remaining testis as adjunct—not replacement—for oncology follow-up.

Overall survival is among the best of solid tumours in young men because platinum cures even advanced IGCCCG good-risk NSGCT in most cases; poor-risk biology still achieves long-term cure in a meaningful subset but needs intensive supportive care. Relapse after initial chemotherapy warrants tertiary subspecialty planning (high-dose strategies, trial enrolment) rather than ad hoc single-agent guesses.

Young men may minimise scrotal symptoms from embarrassment; private wording and chaperone offers improve disclosure. Fertility conversations before cycle one prevent medicolegal regret—document sperm-banking offers and refusals neutrally. When inpatient, align opioid-sparing multimodal analgesia with RPLND/retroperitoneal pain patterns but remain alert for ileus masking opioid needs. Coordinate school or employer absence letters early because financial toxicity drives dropout from surveillance.

• Pre-cycle: temperature, weight, SpO₂ baseline, urine output plan, antiemetic administration timing.
• During BEP: cumulative bleomycin units recorded; breath sounds; magnesium/phosphate replacement slots.
• Neurotoxicity: gate hazards if vibration sense drops or gait widens.
• Psychosocial: intimacy, body-image after orchidectomy prosthesis choice—flag distress scores.

• Suspected torsion or acute ischaemic pain out of proportion to exam.
• Acute dyspnoea, SpO₂ < 92% on room air new for patient, or pleuritic collapse during bleomycin week.
• Seizure, focal deficit, thunderclap headache with known hCG-secreting tumour.
• Fever ≥38 °C while neutropenic on chemotherapy—assume neutropenic sepsis until proven otherwise.

Rising creatinine with poor oral intake during cisplatin days triggers immediate medical review; potassium or calcium derangements may precede obvious oligo-anuria. New oxygen requirement after bleomycin should summon the on-call oncology team and consider high-resolution CT chest—infection and drug toxicity often overlap. Neurological change with metastatic choriocarcinoma escalates to stroke/TIA pathway plus neurosurgery input simultaneously.

Pre-treatment

Verify pregnancy testing policy for partners when relevant, contraception advice (defer conception ~3 months post cisplatin per guideline summaries), hepatitis/HIV screening per unit, and provide translated education leaflets where English is second language.

During treatment

Use central venous access bundles when PICC or port devices are in situ; protect hearing baseline when services offer audiometry; encourage chewing gum for cisplatin-related taste disturbance when tolerated.

Post-treatment

Longitudinal primary care handover should list cumulative cisplatin dose, bleomycin units, radiotherapy field, fertility status, and mental-health referrals. Reinforce second-cancer skin checks for patients also receiving alkylating-type exposures—pair with melanoma sun-safety teaching when field overlap or personal risk intersects.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, ordered response, matrix matching, cloze and multi-patient triage on the topic of tumour-marker stewardship, procedural safety and cisplatin-based toxicity vigilance—mirroring judgement on escalation and surveillance.